NATALIA SOUSA FREITAS QUEIROZ
Projetos de Pesquisa
Unidades Organizacionais
71 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 71
- Long-term real life efficacy of infliximab in Crohn's disease: Brazilian initial experience since 1999(2019) ARCEU, Scanavini Neto; NATALIA, Queiroz; MARCELO, Borba; CARLOS, Sobrado; MAGALY, Teixeira; EDESIO, Silva-Fillho; SERGIO, Nahas; IVAN, Cecconello
bookPart Obstipação(2015) LIMA, Rodrigo Vieira Costa; QUEIROZ, Natália Sousa FreitasbookPart Hemorragia digestiva alta não varicosa(2017) TERRA, Marcela Paes Rosado; QUEIROZ, Natália Sousa FreitasbookPart Métodos de Avaliação Funcional do Trato Gastrintestinal(2016) SANTOS, Ivanna Beserra; QUEIROZ, Natália Sousa Freitas; Sá, Cláudia Cristina de; NAVARRO-RODRIGUEZ, TomásbookPart Obstipação(2023) LIMA, Rodrigo Vieira Costa; QUEIROZ, Natália Sousa Freitas- Long-term effectiveness and safety of ustekinumab in bio-naive and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study(2022) PARRA, Rogerio Serafim; CHEBLI, Julio Maria Fonseca; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao Cintra; AZEVEDO, Matheus Freitas Cardoso de; CHEBLI, Liliana Andrade; BERTGES, Erika Ruback; ALVES JUNIOR, Antonio Jose Tiburcio; AMBROGINI JUNIOR, Orlando; SILVA, Bianca Loyo Pona Schiavetti da; LUBINI, Marcio; BAFUTTO, Mauro; FLORES, Cristina; VILELA, Eduardo Garcia; BORATTO, Sandra Felice; GASPARETTI JUNIOR, Newton Luiz Tricarico; STEINWURZ, Flavio; CARVALHO, Nayara Salgado; FERES, Omar; ROCHA, Jose Joaquim Ribeiro daBackground The effectiveness of ustekinumab (UST) in the treatment of Crohn's disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naive and anti-TNF-exposed patients. Given the selective nature of pivotal trial designs, real-world effectiveness and safety studies are warranted. We report our experience with UST treatment in a large, real-world multicenter cohort of Brazilian patients with CD. Methods We performed a retrospective multicenter study including patients with CD, predominantly biologically refractory CD, who received UST. The primary endpoint was the proportion of patients in clinical remission at weeks 8, 24 and 56. Possible predictors of clinical and biological response/remission and safety outcomes were also assessed. Results Overall, 245 CD (mean age 39.9 [15-87]) patients were enrolled. Most patients (86.5%) had been previously exposed to biologics. According to nonresponder imputation analysis, the proportions of patients in clinical remission at weeks 8, 24 and 56 were 41.0% (n = 98/239), 64.0% (n = 153/239) and 39.3% (n = 94/239), respectively. A biological response was achieved in 55.4% of patients at week 8, and 59.3% were in steroid-free remission at the end of follow-up. No significant differences in either clinical or biological remission were noted between bio-naive and bio-experienced patients. Forty-eight patients (19.6%) presented 60 adverse events during the follow-up, of which 8 (13.3%) were considered serious adverse events (3.2% of 245 patients). Overall, a proximal disease location, younger age, perianal involvement, and smoking were associated with lower rates of clinical remission over time. Conclusions UST therapy was effective and safe in the long term in this large real-life cohort of Brazilian patients with refractory CD, regardless of previous exposure to other biological agents.
- Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area(2021) AZEVEDO, M. F. C. D.; JUSTUS, F. F.; LIMA, C. C. G.; GARCIA, K. S.; BARROS, L. L.; OBA, J.; CARLOS, A. D. S.; MILANI, L. R.; SIPAHI, A. M.; DAMIAO, A. O. M. C.; QUEIROZ, N. S. F.
- Coexistence of Takayasu's Arteritis in Patients with Inflammatory Bowel Diseases(2021) MARTINS, Camilla de Almeida; CAON, Ana Elisa Rabe; FACANALI, Carolina Bortolozzo Graciolli; SOBRADO, Carlos Walter; NAHAS, Sergio Carlos; PEREIRA, Rosa Maria Rodrigues; MARGALIT-YEHUDA, Reuma; KOPYLOV, Uri; QUEIROZ, Natalia Sousa FreitasBackground. Takayasu's arteritis (TA) and inflammatory bowel disease (IBD) are chronic inflammatory granulomatous disorders that have rarely been concomitantly reported in case reports and small case series. Objective. We report a series of seven cases of TA and IBD association in two referral centers with a comprehensive review of literature. Methods. We analyzed retrospectively the electronic medical charts of TA-IBD patients at the University Hospital of Sao Paulo, Brazil, and at the Sheba Medical Center at Tel Aviv University, Israel. Results. Overall, five patients had Crohn's disease (DC) and two had ulcerative colitis (UC), and they were mostly female and non-Asian. All patients developed IBD first and, subsequently, TA. Two underwent colectomy and one ileocecectomy due to IBD activity, while three required cardiovascular surgery due to TA activity. Most patients are currently in clinical remission of both diseases with conventional drug treatment. Conclusion. Although the coexistence of TA and IBD is uncommon, both seem to be strongly associated through pathophysiological pathways.
bookPart Hemorragia digestiva baixa(2017) TERRA, Marcela Paes Rosado; QUEIROZ, Natália Sousa FreitasbookPart Dispepsia e doença ulcerosa péptica(2017) KALIL, Jamile; QUEIROZ, Natália Sousa Freitas